Výsledky vyhledávání - "W. H. Visser"

Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan

Autor: M.D. Ferrari, L.A. Paulsgrove, R.L. Davis, A. M. Rapoport, C.J. Alderton, W. H. Visser, N. R. Cutler

Publikováno v: Neurology. 45:1505-1509

Headache recurrence (HR) may occur within 24 hours in approximately 40% of migraine attacks initially treated successfully with 6 mg subcutaneous (SC) sumatriptan. This may be due to the short plasma half-life of sumatriptan. We studied whether an ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e71aa77946c18a5719879e69938e0d8a
https://doi.org/10.1212/wnl.45.8.1505

Zobrazit plný text záznamu

Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine

Autor: S. Venkatraman, Jan Lewis Brandes, W. H. Visser, Scott A. Reines, Jerome Goldstein, Christopher Lines, Stephen D. Silberstein, William Malbecq, Paul Winner, F. Vrijens, Eric C. Yuen, Merle L. Diamond, Stewart J. Tepper

Publikováno v: Neurology. 62(9)

Objective: To investigate the clinical profile of rofecoxib, a long-acting (≈17-hour half-life) selective cyclo-oxygenase-2 inhibitor, for the acute treatment of migraine.Methods: A randomized, double-blind, placebo-controlled, parallel-group study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10f7afb9b50f8de32d1b6eff358c472c
https://pubmed.ncbi.nlm.nih.gov/15136680

Zobrazit plný text záznamu

Rizatriptan: pharmacological differences from sumatriptan and clinical results

Autor: K A McCarroll, C R Lines, W H Visser

Publikováno v: Current medical research and opinion. 17

Rizatriptan and sumatriptan are selective 5-HT(1B/1D) receptor agonists for theacute treatment of migraine. For oral formulations, the time to maximum plasma concentration is reached earlier with rizatriptan than with sumatriptan (1 h versus 2-2.5 h)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1620ec81c245b9e29a8a25cd993ffed9
https://pubmed.ncbi.nlm.nih.gov/12463279

Zobrazit plný text záznamu

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

Autor: P, Tfelt-Hansen, J, Teall, F, Rodriguez, M, Giacovazzo, J, Paz, W, Malbecq, G A, Block, S A, Reines, W H, Visser

Publikováno v: Headache. 38(10)

Rizatriptan is a potent, oral, 5-HT1B/1D agonist with more rapid absorption and higher bioavailability than oral sumatriptan. It was postulated that this would result in more rapid onset of effect. This randomized, double-blind, triple-dummy, paralle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a90e2ef5a9481d5f373c3c9f6e8d7cd1
https://pubmed.ncbi.nlm.nih.gov/18567177

Zobrazit plný text záznamu

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

Autor: W H, Visser, G M, Terwindt, S A, Reines, K, Jiang, C R, Lines, M D, Ferrari

Publikováno v: Archives of neurology. 53(11)

Rizatriptan (MK-462) is a new 5-hydroxytryptamine1D (serotonin1D; 5-HT1D) receptor agonist for the acute treatment of migraine that has improved pharmacokinetic properties compared with sumatriptan succinate.To assess the efficacy and tolerability of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::323e732d7583ee2fdcfb043fdb00930c
https://pubmed.ncbi.nlm.nih.gov/8912486

Zobrazit plný text záznamu

311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study

Autor: D. Jones, W. H. Visser, K. B. Klein, M.D Ferrari, R. C. Cox

Publikováno v: Neurology. 46(2)

311C90 is a novel, centrally and peripherally, acting 5-hydroxytryptamine1D receptor agonist. We investigated the efficacy and safety of 1, 5, and 25 mg of oral 311C90 in the acute treatment of migraine in a randomized, double-blind, placebo-controll

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c71230094ad687cddfbd18e8f86f1a3
https://pubmed.ncbi.nlm.nih.gov/8614525

Zobrazit plný text záznamu

Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group

Autor: W H, Visser, M D, Ferrari, E M, Bayliss, S, Ludlow, A J, Pilgrim

Publikováno v: Cephalalgia : an international journal of headache. 12(5)

The results of the very first large-scale placebo-controlled dose-response trial with the novel selective 5-hydroxytryptamine1-like (5HT1-like) receptor agonist sumatriptan are presented. We studied the efficacy and tolerability of subcutaneous injec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0a38105a17788e1668cd1bf30b07932f
https://pubmed.ncbi.nlm.nih.gov/1330318

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání